Standard BioTools Inc. (LAB) Stock Competitors & Peer Comparison
See (LAB) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LAB | $1.15 | -9.45% | 448.9M | -8.85 | -$0.13 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $91.07 | +0.32% | 158.6B | 25.51 | $3.57 | +2.68% |
| ISRG | $422.06 | +0.77% | 149.5B | 51.28 | $8.23 | N/A |
| SYK | $305.66 | +1.48% | 117.2B | 35.37 | $8.64 | +1.13% |
| MDT | $81.67 | -0.32% | 104.8B | 21.89 | $3.73 | +3.49% |
| BSX | $48.55 | -0.61% | 72.1B | 20.31 | $2.39 | N/A |
| BRKRP | $421.23 | -8.56% | 64B | N/A | N/A | +0.35% |
| EW | $85.96 | -1.70% | 49.5B | 46.46 | $1.85 | N/A |
| RMD | $196.04 | +0.89% | 28.4B | 18.88 | $10.38 | +1.23% |
Stock Comparison
LAB vs BSX-PA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, LAB is priced at $1.15, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, LAB's ROE is -0.21%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, LAB is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BSX-PA's competition here
LAB vs ABT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ABT has a market cap of 158.6B. Regarding current trading prices, LAB is priced at $1.15, while ABT trades at $91.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ABT's P/E ratio is 25.51. In terms of profitability, LAB's ROE is -0.21%, compared to ABT's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ABT's competition here
LAB vs ISRG Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ISRG has a market cap of 149.5B. Regarding current trading prices, LAB is priced at $1.15, while ISRG trades at $422.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ISRG's P/E ratio is 51.28. In terms of profitability, LAB's ROE is -0.21%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, LAB is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ISRG's competition here
LAB vs SYK Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SYK has a market cap of 117.2B. Regarding current trading prices, LAB is priced at $1.15, while SYK trades at $305.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SYK's P/E ratio is 35.37. In terms of profitability, LAB's ROE is -0.21%, compared to SYK's ROE of +0.15%. Regarding short-term risk, LAB is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SYK's competition here
LAB vs MDT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, MDT has a market cap of 104.8B. Regarding current trading prices, LAB is priced at $1.15, while MDT trades at $81.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas MDT's P/E ratio is 21.89. In terms of profitability, LAB's ROE is -0.21%, compared to MDT's ROE of +0.10%. Regarding short-term risk, LAB is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MDT's competition here
LAB vs BSX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BSX has a market cap of 72.1B. Regarding current trading prices, LAB is priced at $1.15, while BSX trades at $48.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BSX's P/E ratio is 20.31. In terms of profitability, LAB's ROE is -0.21%, compared to BSX's ROE of +0.15%. Regarding short-term risk, LAB is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BSX's competition here
LAB vs BRKRP Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BRKRP has a market cap of 64B. Regarding current trading prices, LAB is priced at $1.15, while BRKRP trades at $421.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BRKRP's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.21%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, LAB is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BRKRP's competition here
LAB vs EW Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, EW has a market cap of 49.5B. Regarding current trading prices, LAB is priced at $1.15, while EW trades at $85.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas EW's P/E ratio is 46.46. In terms of profitability, LAB's ROE is -0.21%, compared to EW's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check EW's competition here
LAB vs RMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, RMD has a market cap of 28.4B. Regarding current trading prices, LAB is priced at $1.15, while RMD trades at $196.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas RMD's P/E ratio is 18.88. In terms of profitability, LAB's ROE is -0.21%, compared to RMD's ROE of +0.24%. Regarding short-term risk, LAB is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check RMD's competition here
LAB vs DXCM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, DXCM has a market cap of 28.1B. Regarding current trading prices, LAB is priced at $1.15, while DXCM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas DXCM's P/E ratio is 31.27. In terms of profitability, LAB's ROE is -0.21%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, LAB is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check DXCM's competition here
LAB vs PHG Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, PHG has a market cap of 25.4B. Regarding current trading prices, LAB is priced at $1.15, while PHG trades at $26.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas PHG's P/E ratio is 22.51. In terms of profitability, LAB's ROE is -0.21%, compared to PHG's ROE of +0.09%. Regarding short-term risk, LAB is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PHG's competition here
LAB vs STE Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, LAB is priced at $1.15, while STE trades at $212.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas STE's P/E ratio is 26.77. In terms of profitability, LAB's ROE is -0.21%, compared to STE's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check STE's competition here
LAB vs ABMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, LAB is priced at $1.15, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ABMD's P/E ratio is 65.36. In terms of profitability, LAB's ROE is -0.21%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, LAB is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ABMD's competition here
LAB vs ZBH Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ZBH has a market cap of 16.9B. Regarding current trading prices, LAB is priced at $1.15, while ZBH trades at $87.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ZBH's P/E ratio is 22.62. In terms of profitability, LAB's ROE is -0.21%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, LAB is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ZBH's competition here
LAB vs SNN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SNN has a market cap of 13B. Regarding current trading prices, LAB is priced at $1.15, while SNN trades at $30.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SNN's P/E ratio is 21.41. In terms of profitability, LAB's ROE is -0.21%, compared to SNN's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SNN's competition here
LAB vs PEN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, LAB is priced at $1.15, while PEN trades at $320.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas PEN's P/E ratio is 74.00. In terms of profitability, LAB's ROE is -0.21%, compared to PEN's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PEN's competition here
LAB vs SWAV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, LAB is priced at $1.15, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SWAV's P/E ratio is 78.76. In terms of profitability, LAB's ROE is -0.21%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, LAB is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SWAV's competition here
LAB vs ALGN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ALGN has a market cap of 12B. Regarding current trading prices, LAB is priced at $1.15, while ALGN trades at $167.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ALGN's P/E ratio is 28.19. In terms of profitability, LAB's ROE is -0.21%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ALGN's competition here
LAB vs GMED Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, LAB is priced at $1.15, while GMED trades at $80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas GMED's P/E ratio is 18.69. In terms of profitability, LAB's ROE is -0.21%, compared to GMED's ROE of +0.13%. Regarding short-term risk, LAB is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check GMED's competition here
LAB vs PODD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, PODD has a market cap of 10.6B. Regarding current trading prices, LAB is priced at $1.15, while PODD trades at $153.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas PODD's P/E ratio is 35.88. In terms of profitability, LAB's ROE is -0.21%, compared to PODD's ROE of +0.21%. Regarding short-term risk, LAB is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PODD's competition here
LAB vs MASI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, LAB is priced at $1.15, while MASI trades at $178.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas MASI's P/E ratio is 44.26. In terms of profitability, LAB's ROE is -0.21%, compared to MASI's ROE of +0.09%. Regarding short-term risk, LAB is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MASI's competition here
LAB vs BIO-B Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BIO-B has a market cap of 8.7B. Regarding current trading prices, LAB is priced at $1.15, while BIO-B trades at $321.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BIO-B's P/E ratio is 53.40. In terms of profitability, LAB's ROE is -0.21%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, LAB is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BIO-B's competition here
LAB vs BRKR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BRKR has a market cap of 8.6B. Regarding current trading prices, LAB is priced at $1.15, while BRKR trades at $56.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BRKR's P/E ratio is -234.96. In terms of profitability, LAB's ROE is -0.21%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, LAB is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BRKR's competition here
LAB vs BIO Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BIO has a market cap of 8B. Regarding current trading prices, LAB is priced at $1.15, while BIO trades at $294.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BIO's P/E ratio is 49.02. In terms of profitability, LAB's ROE is -0.21%, compared to BIO's ROE of +0.02%. Regarding short-term risk, LAB is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BIO's competition here
LAB vs GKOS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, GKOS has a market cap of 7.3B. Regarding current trading prices, LAB is priced at $1.15, while GKOS trades at $125.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas GKOS's P/E ratio is -37.91. In terms of profitability, LAB's ROE is -0.21%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, LAB is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check GKOS's competition here
LAB vs NARI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, LAB is priced at $1.15, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas NARI's P/E ratio is -59.24. In terms of profitability, LAB's ROE is -0.21%, compared to NARI's ROE of -0.00%. Regarding short-term risk, LAB is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NARI's competition here
LAB vs LIVN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, LAB is priced at $1.15, while LIVN trades at $72.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas LIVN's P/E ratio is 36.92. In terms of profitability, LAB's ROE is -0.21%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, LAB is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check LIVN's competition here
LAB vs AXNX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, LAB is priced at $1.15, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas AXNX's P/E ratio is -709.80. In terms of profitability, LAB's ROE is -0.21%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, LAB is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AXNX's competition here
LAB vs IRTC Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, LAB is priced at $1.15, while IRTC trades at $108.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas IRTC's P/E ratio is -127.18. In terms of profitability, LAB's ROE is -0.21%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, LAB is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check IRTC's competition here
LAB vs ITGR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, LAB is priced at $1.15, while ITGR trades at $91.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ITGR's P/E ratio is 22.82. In terms of profitability, LAB's ROE is -0.21%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, LAB is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ITGR's competition here
LAB vs TMDX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, LAB is priced at $1.15, while TMDX trades at $69.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas TMDX's P/E ratio is 15.89. In terms of profitability, LAB's ROE is -0.21%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, LAB is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check TMDX's competition here
LAB vs AXGN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, LAB is priced at $1.15, while AXGN trades at $42.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas AXGN's P/E ratio is -66.87. In terms of profitability, LAB's ROE is -0.21%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, LAB is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AXGN's competition here
LAB vs ESTA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, LAB is priced at $1.15, while ESTA trades at $74.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ESTA's P/E ratio is -50.55. In terms of profitability, LAB's ROE is -0.21%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, LAB is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ESTA's competition here
LAB vs NUVA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, LAB is priced at $1.15, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas NUVA's P/E ratio is 75.00. In terms of profitability, LAB's ROE is -0.21%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, LAB is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NUVA's competition here
LAB vs UFPT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, LAB is priced at $1.15, while UFPT trades at $223.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas UFPT's P/E ratio is 25.47. In terms of profitability, LAB's ROE is -0.21%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, LAB is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check UFPT's competition here
LAB vs PRCT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, LAB is priced at $1.15, while PRCT trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas PRCT's P/E ratio is -15.21. In terms of profitability, LAB's ROE is -0.21%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, LAB is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PRCT's competition here
LAB vs ENOV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, LAB is priced at $1.15, while ENOV trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ENOV's P/E ratio is -1.20. In terms of profitability, LAB's ROE is -0.21%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, LAB is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ENOV's competition here
LAB vs AHCO Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, LAB is priced at $1.15, while AHCO trades at $9.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas AHCO's P/E ratio is -16.76. In terms of profitability, LAB's ROE is -0.21%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, LAB is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AHCO's competition here
LAB vs TNDM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, LAB is priced at $1.15, while TNDM trades at $19.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas TNDM's P/E ratio is -14.12. In terms of profitability, LAB's ROE is -0.21%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, LAB is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check TNDM's competition here
LAB vs IART Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, LAB is priced at $1.15, while IART trades at $16.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas IART's P/E ratio is -2.63. In terms of profitability, LAB's ROE is -0.21%, compared to IART's ROE of -0.48%. Regarding short-term risk, LAB is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check IART's competition here
LAB vs HSKA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, LAB is priced at $1.15, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas HSKA's P/E ratio is -62.49. In terms of profitability, LAB's ROE is -0.21%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, LAB is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check HSKA's competition here
LAB vs ATEC Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $1.15, while ATEC trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ATEC's P/E ratio is -9.64. In terms of profitability, LAB's ROE is -0.21%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, LAB is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ATEC's competition here
LAB vs BFLY Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $1.15, while BFLY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BFLY's P/E ratio is -15.20. In terms of profitability, LAB's ROE is -0.21%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, LAB is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BFLY's competition here
LAB vs IRMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $1.15, while IRMD trades at $93.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas IRMD's P/E ratio is 50.86. In terms of profitability, LAB's ROE is -0.21%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, LAB is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check IRMD's competition here
LAB vs INSP Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $1.15, while INSP trades at $41.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas INSP's P/E ratio is 9.36. In terms of profitability, LAB's ROE is -0.21%, compared to INSP's ROE of +0.18%. Regarding short-term risk, LAB is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check INSP's competition here
LAB vs AVNS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $1.15, while AVNS trades at $25.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas AVNS's P/E ratio is -15.66. In terms of profitability, LAB's ROE is -0.21%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, LAB is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AVNS's competition here
LAB vs SILK Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, LAB is priced at $1.15, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SILK's P/E ratio is -18.96. In terms of profitability, LAB's ROE is -0.21%, compared to SILK's ROE of -0.35%. Regarding short-term risk, LAB is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SILK's competition here
LAB vs FNA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, LAB is priced at $1.15, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas FNA's P/E ratio is -19.83. In terms of profitability, LAB's ROE is -0.21%, compared to FNA's ROE of -0.35%. Regarding short-term risk, LAB is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check FNA's competition here
LAB vs CNMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, LAB is priced at $1.15, while CNMD trades at $35.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CNMD's P/E ratio is 19.84. In terms of profitability, LAB's ROE is -0.21%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, LAB is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CNMD's competition here
LAB vs AORT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, AORT has a market cap of 977.7M. Regarding current trading prices, LAB is priced at $1.15, while AORT trades at $20.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas AORT's P/E ratio is 80.56. In terms of profitability, LAB's ROE is -0.21%, compared to AORT's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AORT's competition here
LAB vs CSII Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, LAB is priced at $1.15, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CSII's P/E ratio is -20.83. In terms of profitability, LAB's ROE is -0.21%, compared to CSII's ROE of -0.14%. Regarding short-term risk, LAB is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CSII's competition here
LAB vs INMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, INMD has a market cap of 823.4M. Regarding current trading prices, LAB is priced at $1.15, while INMD trades at $13.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas INMD's P/E ratio is 10.03. In terms of profitability, LAB's ROE is -0.21%, compared to INMD's ROE of +0.13%. Regarding short-term risk, LAB is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check INMD's competition here
LAB vs LMRI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, LMRI has a market cap of 816.7M. Regarding current trading prices, LAB is priced at $1.15, while LMRI trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas LMRI's P/E ratio is -21.79. In terms of profitability, LAB's ROE is -0.21%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, LAB is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check LMRI's competition here
LAB vs SSII Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SSII has a market cap of 756.5M. Regarding current trading prices, LAB is priced at $1.15, while SSII trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SSII's P/E ratio is -75.60. In terms of profitability, LAB's ROE is -0.21%, compared to SSII's ROE of -0.23%. Regarding short-term risk, LAB is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SSII's competition here
LAB vs CRY Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, LAB is priced at $1.15, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CRY's P/E ratio is 425.71. In terms of profitability, LAB's ROE is -0.21%, compared to CRY's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CRY's competition here
LAB vs CBLL Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CBLL has a market cap of 692.5M. Regarding current trading prices, LAB is priced at $1.15, while CBLL trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CBLL's P/E ratio is -11.27. In terms of profitability, LAB's ROE is -0.21%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, LAB is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CBLL's competition here
LAB vs SIBN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SIBN has a market cap of 670.6M. Regarding current trading prices, LAB is priced at $1.15, while SIBN trades at $15.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SIBN's P/E ratio is -38.77. In terms of profitability, LAB's ROE is -0.21%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, LAB is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SIBN's competition here
LAB vs SRDX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, LAB is priced at $1.15, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SRDX's P/E ratio is -34.66. In terms of profitability, LAB's ROE is -0.21%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, LAB is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SRDX's competition here
LAB vs BVS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BVS has a market cap of 612.4M. Regarding current trading prices, LAB is priced at $1.15, while BVS trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BVS's P/E ratio is 22.05. In terms of profitability, LAB's ROE is -0.21%, compared to BVS's ROE of +0.16%. Regarding short-term risk, LAB is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BVS's competition here
LAB vs APEN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, LAB is priced at $1.15, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas APEN's P/E ratio is -9.43. In terms of profitability, LAB's ROE is -0.21%, compared to APEN's ROE of -0.85%. Regarding short-term risk, LAB is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check APEN's competition here
LAB vs TCMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, TCMD has a market cap of 572.9M. Regarding current trading prices, LAB is priced at $1.15, while TCMD trades at $25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas TCMD's P/E ratio is 29.20. In terms of profitability, LAB's ROE is -0.21%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, LAB is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check TCMD's competition here
LAB vs BWAY Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BWAY has a market cap of 544.8M. Regarding current trading prices, LAB is priced at $1.15, while BWAY trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BWAY's P/E ratio is 63.14. In terms of profitability, LAB's ROE is -0.21%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BWAY's competition here
LAB vs CERS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CERS has a market cap of 543M. Regarding current trading prices, LAB is priced at $1.15, while CERS trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CERS's P/E ratio is -54.20. In terms of profitability, LAB's ROE is -0.21%, compared to CERS's ROE of -0.15%. Regarding short-term risk, LAB is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CERS's competition here
LAB vs NPCE Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, NPCE has a market cap of 536.6M. Regarding current trading prices, LAB is priced at $1.15, while NPCE trades at $15.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas NPCE's P/E ratio is -24.22. In terms of profitability, LAB's ROE is -0.21%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, LAB is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NPCE's competition here
LAB vs ZIMV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, LAB is priced at $1.15, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, LAB's ROE is -0.21%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, LAB is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ZIMV's competition here
LAB vs CTKB Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CTKB has a market cap of 528.2M. Regarding current trading prices, LAB is priced at $1.15, while CTKB trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CTKB's P/E ratio is -7.05. In terms of profitability, LAB's ROE is -0.21%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, LAB is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CTKB's competition here
LAB vs KIDS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, KIDS has a market cap of 470.5M. Regarding current trading prices, LAB is priced at $1.15, while KIDS trades at $18.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas KIDS's P/E ratio is -10.90. In terms of profitability, LAB's ROE is -0.21%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, LAB is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check KIDS's competition here
LAB vs PACB Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, PACB has a market cap of 450.4M. Regarding current trading prices, LAB is priced at $1.15, while PACB trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas PACB's P/E ratio is -3.54. In terms of profitability, LAB's ROE is -0.21%, compared to PACB's ROE of -4.88%. Regarding short-term risk, LAB is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check PACB's competition here
LAB vs VREX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, VREX has a market cap of 424.8M. Regarding current trading prices, LAB is priced at $1.15, while VREX trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas VREX's P/E ratio is -5.04. In terms of profitability, LAB's ROE is -0.21%, compared to VREX's ROE of -0.18%. Regarding short-term risk, LAB is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check VREX's competition here
LAB vs OFIX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, OFIX has a market cap of 415.9M. Regarding current trading prices, LAB is priced at $1.15, while OFIX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas OFIX's P/E ratio is -6.86. In terms of profitability, LAB's ROE is -0.21%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, LAB is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check OFIX's competition here
LAB vs PMI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, PMI has a market cap of 403.9M. Regarding current trading prices, LAB is priced at $1.15, while PMI trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas PMI's P/E ratio is -0.34. In terms of profitability, LAB's ROE is -0.21%, compared to PMI's ROE of +4.99%. Regarding short-term risk, LAB is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check PMI's competition here
LAB vs CLPT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CLPT has a market cap of 386.6M. Regarding current trading prices, LAB is priced at $1.15, while CLPT trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CLPT's P/E ratio is -12.89. In terms of profitability, LAB's ROE is -0.21%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, LAB is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CLPT's competition here
LAB vs VMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, VMD has a market cap of 382.2M. Regarding current trading prices, LAB is priced at $1.15, while VMD trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas VMD's P/E ratio is 26.95. In terms of profitability, LAB's ROE is -0.21%, compared to VMD's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check VMD's competition here
LAB vs DCTH Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, DCTH has a market cap of 368.3M. Regarding current trading prices, LAB is priced at $1.15, while DCTH trades at $10.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas DCTH's P/E ratio is 1067.00. In terms of profitability, LAB's ROE is -0.21%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, LAB is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check DCTH's competition here
LAB vs AVR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, AVR has a market cap of 354.6M. Regarding current trading prices, LAB is priced at $1.15, while AVR trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas AVR's P/E ratio is -4.34. In terms of profitability, LAB's ROE is -0.21%, compared to AVR's ROE of -1.24%. Regarding short-term risk, LAB is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AVR's competition here
LAB vs ELMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ELMD has a market cap of 313.9M. Regarding current trading prices, LAB is priced at $1.15, while ELMD trades at $37.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ELMD's P/E ratio is 32.40. In terms of profitability, LAB's ROE is -0.21%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, LAB is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ELMD's competition here
LAB vs SMLR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, LAB is priced at $1.15, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SMLR's P/E ratio is 3.92. In terms of profitability, LAB's ROE is -0.21%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, LAB is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SMLR's competition here
LAB vs MASS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, MASS has a market cap of 299.9M. Regarding current trading prices, LAB is priced at $1.15, while MASS trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas MASS's P/E ratio is -8.18. In terms of profitability, LAB's ROE is -0.21%, compared to MASS's ROE of -0.26%. Regarding short-term risk, LAB is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MASS's competition here
LAB vs SENS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SENS has a market cap of 278.6M. Regarding current trading prices, LAB is priced at $1.15, while SENS trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SENS's P/E ratio is -3.39. In terms of profitability, LAB's ROE is -0.21%, compared to SENS's ROE of -1.30%. Regarding short-term risk, LAB is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SENS's competition here
LAB vs MGRM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, LAB is priced at $1.15, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas MGRM's P/E ratio is -11.11. In terms of profitability, LAB's ROE is -0.21%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, LAB is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MGRM's competition here
LAB vs SGHT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SGHT has a market cap of 242.1M. Regarding current trading prices, LAB is priced at $1.15, while SGHT trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SGHT's P/E ratio is -6.36. In terms of profitability, LAB's ROE is -0.21%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, LAB is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SGHT's competition here
LAB vs CATX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CATX has a market cap of 232.9M. Regarding current trading prices, LAB is priced at $1.15, while CATX trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CATX's P/E ratio is -2.14. In terms of profitability, LAB's ROE is -0.21%, compared to CATX's ROE of -0.42%. Regarding short-term risk, LAB is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CATX's competition here
LAB vs TMCI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, TMCI has a market cap of 227.7M. Regarding current trading prices, LAB is priced at $1.15, while TMCI trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas TMCI's P/E ratio is -3.66. In terms of profitability, LAB's ROE is -0.21%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, LAB is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check TMCI's competition here
LAB vs NVRO Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, LAB is priced at $1.15, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas NVRO's P/E ratio is -1.91. In terms of profitability, LAB's ROE is -0.21%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, LAB is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NVRO's competition here
LAB vs EYES Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, LAB is priced at $1.15, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas EYES's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.21%, compared to EYES's ROE of -2.64%. Regarding short-term risk, LAB is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check EYES's competition here
LAB vs RXST Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, RXST has a market cap of 207M. Regarding current trading prices, LAB is priced at $1.15, while RXST trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas RXST's P/E ratio is -4.42. In terms of profitability, LAB's ROE is -0.21%, compared to RXST's ROE of -0.17%. Regarding short-term risk, LAB is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check RXST's competition here
LAB vs PROF Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, PROF has a market cap of 201.5M. Regarding current trading prices, LAB is priced at $1.15, while PROF trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas PROF's P/E ratio is -5.37. In terms of profitability, LAB's ROE is -0.21%, compared to PROF's ROE of -0.71%. Regarding short-term risk, LAB is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PROF's competition here
LAB vs ANIK Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, ANIK has a market cap of 192.7M. Regarding current trading prices, LAB is priced at $1.15, while ANIK trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas ANIK's P/E ratio is -18.33. In terms of profitability, LAB's ROE is -0.21%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, LAB is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ANIK's competition here
LAB vs BSGM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, LAB is priced at $1.15, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas BSGM's P/E ratio is -5.81. In terms of profitability, LAB's ROE is -0.21%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, LAB is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check BSGM's competition here
LAB vs APYX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, APYX has a market cap of 187.2M. Regarding current trading prices, LAB is priced at $1.15, while APYX trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas APYX's P/E ratio is -20.32. In terms of profitability, LAB's ROE is -0.21%, compared to APYX's ROE of -0.91%. Regarding short-term risk, LAB is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check APYX's competition here
LAB vs MDGS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, LAB is priced at $1.15, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas MDGS's P/E ratio is -0.27. In terms of profitability, LAB's ROE is -0.21%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, LAB is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check MDGS's competition here
LAB vs EDAP Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, LAB is priced at $1.15, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas EDAP's P/E ratio is -5.80. In terms of profitability, LAB's ROE is -0.21%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, LAB is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check EDAP's competition here
LAB vs INGN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, INGN has a market cap of 173.5M. Regarding current trading prices, LAB is priced at $1.15, while INGN trades at $6.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas INGN's P/E ratio is -7.04. In terms of profitability, LAB's ROE is -0.21%, compared to INGN's ROE of -0.13%. Regarding short-term risk, LAB is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check INGN's competition here
LAB vs QIPT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, LAB is priced at $1.15, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas QIPT's P/E ratio is -15.87. In terms of profitability, LAB's ROE is -0.21%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, LAB is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check QIPT's competition here
LAB vs QTRX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, QTRX has a market cap of 155.4M. Regarding current trading prices, LAB is priced at $1.15, while QTRX trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas QTRX's P/E ratio is -1.40. In terms of profitability, LAB's ROE is -0.21%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, LAB is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check QTRX's competition here
LAB vs CVRX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, CVRX has a market cap of 142.8M. Regarding current trading prices, LAB is priced at $1.15, while CVRX trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas CVRX's P/E ratio is -2.68. In terms of profitability, LAB's ROE is -0.21%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, LAB is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CVRX's competition here
LAB vs NNOX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, NNOX has a market cap of 134.3M. Regarding current trading prices, LAB is priced at $1.15, while NNOX trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas NNOX's P/E ratio is -1.66. In terms of profitability, LAB's ROE is -0.21%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, LAB is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NNOX's competition here
LAB vs SNWV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, SNWV has a market cap of 126.9M. Regarding current trading prices, LAB is priced at $1.15, while SNWV trades at $14.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas SNWV's P/E ratio is 15.38. In terms of profitability, LAB's ROE is -0.21%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, LAB is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SNWV's competition here
LAB vs MXCT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 448.9M. In comparison, MXCT has a market cap of 122.1M. Regarding current trading prices, LAB is priced at $1.15, while MXCT trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -8.85, whereas MXCT's P/E ratio is -3.17. In terms of profitability, LAB's ROE is -0.21%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, LAB is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MXCT's competition here